haloperidol has been researched along with Electrocardiogram QT Prolonged in 56 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to estimate the effects of intramuscular haloperidol and lorazepam on the QT interval in volunteers with schizophrenia." | 9.11 | Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. ( Burke, M; Flockhart, D; Gorski, JC; Greenblatt, DJ; Harvey, AT; Preskorn, SH; Werder, S, 2004) |
| "Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile." | 9.10 | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 9.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "To report a case of torsade de pointes related to the administration of high-dose intravenous haloperidol for the treatment of severe agitation." | 7.70 | Haloperidol-induced torsade de pointes. ( O'Brien, JM; Rockwood, RP; Suh, KI, 1999) |
| "A patient is described who developed hypokalemia and cardiac arrhythmia after acute intoxication with haloperidol." | 7.67 | Prolonged Q-T interval and hypokalemia caused by haloperidol. ( Aunsholt, NA, 1989) |
| "The objective of this study was to estimate the effects of intramuscular haloperidol and lorazepam on the QT interval in volunteers with schizophrenia." | 5.11 | Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. ( Burke, M; Flockhart, D; Gorski, JC; Greenblatt, DJ; Harvey, AT; Preskorn, SH; Werder, S, 2004) |
| "Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile." | 5.10 | Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. ( Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL, 2002) |
| " Databases included: placebo-controlled [two schizophrenia, one bipolar mania trials (n=565)]; haloperidol-controlled [two schizophrenia trials (n=482)]; geriatric placebo-controlled [1 dementia trial (n=204)]." | 5.10 | Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. ( Alaka, K; Beasley, CM; Lindborg, SR; Taylor, CC, 2003) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 5.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "These results indicated that low-dose intravenous haloperidol was safe and not clinically relevant for the development of a newly onset long QT syndrome or adverse outcomes and support recent findings inside and outside the ICU setting." | 5.05 | QTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery: A cohort study and review of the literature. ( Bettex, D; Boettger, S; Burbuqe, I; Rudiger, A; Schubert, M, 2020) |
| "Many drugs, including haloperidol, are linked with a risk of QTc-prolongation, which can lead to Torsade de Pointes and sudden cardiac death." | 3.83 | Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium. ( Foulon, V; Spriet, I; Vandael, E; Vandenberghe, J; Vandenberk, B; Willems, R, 2016) |
| "Medical records were reviewed retrospectively to identify consecutive patients who were admitted to our neuropsychiatry service with the presenting complaint of dementia (DSM-IV) with agitation and who were given intramuscular ziprasidone and then administered an electrocardiogram (ECG) (N = 23)." | 3.73 | A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. ( Brown, FW; Greco, KE; Tune, LE; Van Horn, WA, 2005) |
| "A 42-year-old woman who underwent single lung transplantation who received tacrolimus and a 58-year-old woman with pneumonia and multiple comorbidities who received haloperidol both experienced drug-induced prolongation of cardiac repolarization." | 3.72 | Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient. ( Akers, WS; Davis, GA; Flynn, JD; Green, AE; Strobel, G; Winstead, PS, 2004) |
| "To report a case of torsade de pointes related to the administration of high-dose intravenous haloperidol for the treatment of severe agitation." | 3.70 | Haloperidol-induced torsade de pointes. ( O'Brien, JM; Rockwood, RP; Suh, KI, 1999) |
| "A patient is described who developed hypokalemia and cardiac arrhythmia after acute intoxication with haloperidol." | 3.67 | Prolonged Q-T interval and hypokalemia caused by haloperidol. ( Aunsholt, NA, 1989) |
| " The pharmacokinetics of haloperidol and its pharmacodynamic effects measured for QTc prolongation and neurologic side effects were evaluated after a single dose of 5 mg haloperidol following a pretreatment of placebo or itraconazole at 200 mg/d for 10 days in a randomized crossover manner." | 2.72 | Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ( Cha, IJ; Jung, HJ; Kim, KA; Park, JY; Shim, JC; Shin, JG; Shon, JH; Yoon, YR, 2006) |
| "Haloperidol at high dosage is associated with QTc prolongation and polymorphic ventricular arrhythmia but the effects of low-dose haloperidol remain unknown." | 1.56 | Should we still monitor QTc duration in frail older patients on low-dose haloperidol? A prospective observational cohort study. ( Bordachar, P; Castro, E; Hazebroek, M; Körver, F; Merry, A; Ploux, S; Prinzen, F; Sipers, W; Smid, M; Strik, M; van Moorsel, F, 2020) |
| "To determine the most common drug-drug interaction (DDI) pairs contributing to QTc prolongation in cardiac intensive care units (ICUs)." | 1.39 | Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. ( Armahizer, MJ; Kane-Gill, SL; Seybert, AL; Smithburger, PL, 2013) |
| "(1) The first-line drug for the treatment of schizophrenic disorders is a neuroleptic such as haloperidol." | 1.34 | Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation. ( , 2007) |
| "Haloperidol has been reported to induce polymorphic ventricular arrhythmias associated with QT prolongation." | 1.31 | Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential. ( Hashimoto, K; Satoh, Y; Sugiyama, A; Tamura, K, 2000) |
| "4." | 1.30 | The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. ( Attali, B; Busch, AE; Heinemann, SH; Lang, F; Schönherr, R; Suessbrich, H, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.79) | 18.7374 |
| 1990's | 6 (10.71) | 18.2507 |
| 2000's | 29 (51.79) | 29.6817 |
| 2010's | 16 (28.57) | 24.3611 |
| 2020's | 4 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Recanatini, M | 1 |
| Arditti, R | 1 |
| Mongin, Y | 1 |
| Drancourt, N | 1 |
| Hotier, S | 1 |
| Laguerre, A | 1 |
| Hamdani, N | 1 |
| Burbuqe, I | 1 |
| Boettger, S | 1 |
| Schubert, M | 1 |
| Bettex, D | 1 |
| Rudiger, A | 1 |
| Castro, E | 1 |
| Körver, F | 1 |
| Merry, A | 1 |
| van Moorsel, F | 1 |
| Hazebroek, M | 1 |
| Smid, M | 1 |
| Ploux, S | 1 |
| Bordachar, P | 1 |
| Prinzen, F | 1 |
| Sipers, W | 1 |
| Strik, M | 1 |
| Potnuri, AG | 1 |
| Reddy, KP | 1 |
| Suresh, P | 1 |
| Husain, GM | 1 |
| Kazmi, MH | 1 |
| Harishankar, N | 1 |
| Schmidt, A | 1 |
| Fischer, P | 2 |
| Wally, B | 1 |
| Scharfetter, J | 2 |
| Fernandes, FM | 1 |
| Silva, EP | 1 |
| Martins, RR | 1 |
| Oliveira, AG | 1 |
| Vesely, P | 1 |
| Stracina, T | 1 |
| Hlavacova, M | 1 |
| Halamek, J | 1 |
| Kolarova, J | 1 |
| Olejnickova, V | 1 |
| Mrkvicova, V | 1 |
| Paulova, H | 1 |
| Novakova, M | 1 |
| Warnier, MJ | 1 |
| Rutten, FH | 1 |
| Souverein, PC | 1 |
| de Boer, A | 2 |
| Hoes, AW | 1 |
| De Bruin, ML | 1 |
| Vandael, E | 2 |
| Vandenberk, B | 2 |
| Vandenberghe, J | 2 |
| Spriet, I | 2 |
| Willems, R | 2 |
| Foulon, V | 2 |
| Barbui, C | 1 |
| Bighelli, I | 1 |
| Carrà, G | 1 |
| Castellazzi, M | 1 |
| Lucii, C | 1 |
| Martinotti, G | 1 |
| Nosè, M | 1 |
| Ostuzzi, G | 1 |
| Duprey, MS | 1 |
| Al-Qadheeb, N | 1 |
| Roberts, R | 1 |
| Skrobik, Y | 1 |
| Schumaker, G | 1 |
| Devlin, JW | 1 |
| Bush, SE | 1 |
| Hatton, RC | 1 |
| Winterstein, AG | 1 |
| Thomson, MR | 1 |
| Woo, GW | 1 |
| Stepkovitch, K | 1 |
| Heagle Bahn, C | 1 |
| Gupta, R | 1 |
| Cherry, JG | 1 |
| Ng, TM | 1 |
| Olsen, KM | 1 |
| McCartan, MA | 1 |
| Puumala, SE | 1 |
| Speidel, KM | 1 |
| Miller, MA | 1 |
| Sears, TD | 1 |
| Mukherji, EH | 1 |
| Bauer, LK | 1 |
| Leskov, I | 1 |
| Januzzi, JL | 1 |
| Tanev, KS | 1 |
| Blom, MT | 1 |
| Bardai, A | 1 |
| van Munster, BC | 1 |
| Nieuwland, MI | 1 |
| de Jong, H | 1 |
| van Hoeijen, DA | 1 |
| Spanjaart, AM | 1 |
| de Rooij, SE | 1 |
| Tan, HL | 1 |
| Suzuki, Y | 1 |
| Watanabe, J | 1 |
| Sugai, T | 1 |
| Fukui, N | 1 |
| Ono, S | 1 |
| Tsuneyama, N | 1 |
| Saito, M | 1 |
| Someya, T | 1 |
| Muzyk, AJ | 2 |
| Rayfield, A | 2 |
| Revollo, JY | 1 |
| Heinz, H | 2 |
| Gagliardi, JP | 2 |
| Rivelli, SK | 1 |
| Jiang, W | 1 |
| Armahizer, MJ | 1 |
| Seybert, AL | 1 |
| Smithburger, PL | 1 |
| Kane-Gill, SL | 1 |
| LLerena, A | 1 |
| Berecz, R | 1 |
| de la Rubia, A | 1 |
| Dorado, P | 1 |
| Kane, JM | 1 |
| Carson, WH | 1 |
| Saha, AR | 1 |
| McQuade, RD | 1 |
| Ingenito, GG | 1 |
| Zimbroff, DL | 1 |
| Ali, MW | 1 |
| Su, KP | 2 |
| Shen, WW | 2 |
| Chuang, CL | 1 |
| Chen, KP | 1 |
| Chen, CC | 1 |
| Mörtl, D | 1 |
| Agneter, E | 1 |
| Krivanek, P | 1 |
| Koppatz, K | 1 |
| Todt, H | 1 |
| Sugiyama, A | 2 |
| Lindborg, SR | 1 |
| Beasley, CM | 2 |
| Alaka, K | 1 |
| Taylor, CC | 1 |
| Zareba, W | 1 |
| Lin, DA | 1 |
| Harrigan, EP | 1 |
| Miceli, JJ | 1 |
| Anziano, R | 1 |
| Watsky, E | 1 |
| Reeves, KR | 1 |
| Cutler, NR | 1 |
| Sramek, J | 1 |
| Shiovitz, T | 1 |
| Middle, M | 1 |
| Akers, WS | 1 |
| Flynn, JD | 1 |
| Davis, GA | 1 |
| Green, AE | 1 |
| Winstead, PS | 1 |
| Strobel, G | 1 |
| Vella-Brincat, J | 1 |
| Macleod, AD | 1 |
| Harvey, AT | 1 |
| Flockhart, D | 1 |
| Gorski, JC | 1 |
| Greenblatt, DJ | 1 |
| Burke, M | 1 |
| Werder, S | 1 |
| Preskorn, SH | 1 |
| Vieweg, WV | 1 |
| Greco, KE | 1 |
| Tune, LE | 1 |
| Brown, FW | 1 |
| Van Horn, WA | 1 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Abe, J | 1 |
| Sawada, Y | 1 |
| Hashimoto, K | 2 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Kano, M | 1 |
| Toyoshi, T | 1 |
| Iwasaki, S | 1 |
| Kato, M | 1 |
| Shimizu, M | 1 |
| Ota, T | 1 |
| Park, JY | 1 |
| Shon, JH | 1 |
| Kim, KA | 1 |
| Jung, HJ | 1 |
| Shim, JC | 1 |
| Yoon, YR | 1 |
| Cha, IJ | 1 |
| Shin, JG | 1 |
| Roberts-Thomson, KC | 1 |
| Teo, KS | 1 |
| Young, GD | 1 |
| Katagai, H | 1 |
| Yasui-Furukori, N | 1 |
| Kikuchi, A | 1 |
| Kaneko, S | 1 |
| Leo, R | 1 |
| Razzini, C | 1 |
| Di Lorenzo, G | 1 |
| Bianchi, F | 1 |
| Tesauro, M | 1 |
| Zanasi, M | 1 |
| Siracusano, A | 1 |
| Romeo, F | 1 |
| Metzger, E | 1 |
| Friedman, R | 1 |
| Iwahashi, K | 2 |
| Nakamura, K | 1 |
| Miyatake, R | 1 |
| Suwaki, H | 1 |
| Hosokawa, K | 1 |
| Suessbrich, H | 1 |
| Schönherr, R | 1 |
| Heinemann, SH | 1 |
| Attali, B | 1 |
| Lang, F | 1 |
| Busch, AE | 1 |
| O'Brien, JM | 1 |
| Rockwood, RP | 1 |
| Suh, KI | 1 |
| Pohjola-Sintonen, S | 1 |
| Metsäniitty, J | 1 |
| Satoh, Y | 1 |
| Tamura, K | 1 |
| Czekalla, J | 1 |
| Dellva, MA | 1 |
| Berg, PH | 1 |
| Grundy, S | 1 |
| Hatta, K | 1 |
| Takahashi, T | 1 |
| Nakamura, H | 1 |
| Yamashiro, H | 1 |
| Asukai, N | 1 |
| Matsuzaki, I | 1 |
| Yonezawa, Y | 1 |
| Chang, HC | 1 |
| Taylor, DM | 1 |
| Aunsholt, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Observational Study to Evaluate the Effects on the Qt Interval of COVID-19 Coronavirus Infection in Critically Ill Patients[NCT04422535] | 80 participants (Anticipated) | Observational | 2020-05-29 | Recruiting | |||
| Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital[NCT02068170] | 178 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| Aripiprazole, Abilify Maintena Collaborative Clinical Protocol[NCT02717130] | 9 participants (Actual) | Interventional | 2016-06-08 | Terminated (stopped due to The study was terminated due to lack of enrollment.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for haloperidol and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
QTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery: A cohort study and review of the literature.
Topics: Aged; Cardiac Surgical Procedures; Cohort Studies; Electrocardiography; Female; Haloperidol; Humans; | 2020 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cat | 2003 |
Antipsychotic drugs and QT interval prolongation.
Topics: Age Factors; Algorithms; Antipsychotic Agents; Benzodiazepines; Death, Sudden, Cardiac; Dopamine Ant | 2003 |
Haloperidol in palliative care.
Topics: Antipsychotic Agents; Conscious Sedation; Delirium; Haloperidol; Humans; Long QT Syndrome; Nausea; V | 2004 |
9 trials available for haloperidol and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial.
Topics: Adult; Aged; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Double-Blind Method; | 2016 |
QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Debrisoquin; Female; Gas Chromatography-Mas | 2002 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Doubl | 2002 |
A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Cross-Over Studies; Female; Haloperidol; Heart Conduction S | 2003 |
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Dose-Response Relationship, Drug; | 2003 |
A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.
Topics: Adolescent; Adult; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Benzodiazepines; Biotransfor | 2004 |
Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
Topics: Adult; Confidence Intervals; Cross-Over Studies; Electrocardiography; Female; Haloperidol; Humans; I | 2004 |
Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
Topics: Adult; Akathisia, Drug-Induced; Antifungal Agents; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Cy | 2006 |
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agent | 2001 |
43 other studies available for haloperidol and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go- | 2002 |
[Hypothermia due to antipsychotic drug: A case report].
Topics: Adult; Antipsychotic Agents; Consciousness Disorders; Drug Substitution; Female; Haloperidol; Humans | 2020 |
Should we still monitor QTc duration in frail older patients on low-dose haloperidol? A prospective observational cohort study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Electrocardiography; Female; Frail Elderly; Haloperid | 2020 |
Obesity Potentiates the Risk of Drug-Induced Long QT Syndrome - Preliminary Evidence from WNIN/Ob Spontaneously Obese Rat.
Topics: Adiposity; Animals; Antipsychotic Agents; Cardiomegaly; Disease Models, Animal; Female; Haloperidol; | 2021 |
Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval.
Topics: Adult; Antipsychotic Agents; Benperidol; Case-Control Studies; Electrocardiography; Female; Haloperi | 2017 |
QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications.
Topics: Adult; Aged; Amiodarone; Clopidogrel; Critical Illness; Cross-Sectional Studies; Electrocardiography | 2018 |
Haloperidol affects coupling between QT and RR intervals in guinea pig isolated heart.
Topics: Animals; Antipsychotic Agents; Guinea Pigs; Haloperidol; Heart; Heart Rate; Long QT Syndrome; Male | 2019 |
[QTc prolongation induced by intravenous sedation with Haloperidol, Prothipendyl and Lorazepam].
Topics: Adult; Age Factors; Aged; Comorbidity; Conscious Sedation; Drug Synergism; Drug Therapy, Combination | 2014 |
Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Monitoring; Drug Prescriptions; Drug-Related Side E | 2015 |
Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Belgium; Electrocardiography; Follow-Up Studie | 2016 |
Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Cross-Sectional Studies; Dose-Re | 2016 |
Development of a risk score for QTc-prolongation: the RISQ-PATH study.
Topics: Aged; Female; Fluconazole; Haloperidol; Humans; Levofloxacin; Long QT Syndrome; Male; Models, Statis | 2017 |
Effects of concomitant amiodarone and haloperidol on Q-Tc interval prolongation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antipsychotic Agents; Drug Therapy, Combination; Electroca | 2008 |
Low-dose haloperidol-associated QTc prolongation.
Topics: Aged, 80 and over; Antipsychotic Agents; Female; Haloperidol; Humans; Long QT Syndrome; Male | 2008 |
Interpreting data about prolongation of the Q-Tc interval induced by amiodarone and haloperidol.
Topics: Amiodarone; Data Interpretation, Statistical; Drug Therapy, Combination; Haloperidol; Humans; Long Q | 2009 |
Drug-induced QTc-interval prolongation in the intensive care unit: incidence and predictors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Female; Fluoroquinolones; Haloperidol; Human | 2010 |
Safety of antipsychotics in the setting of QTc prolongation: the utility of the JT index.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Bundle-Branch Block; Combined Modality T | 2011 |
Differential changes in QTc duration during in-hospital haloperidol use.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Electrocardiography; Haloperidol; Hospitalization; Ho | 2011 |
Improvement in QTc prolongation induced by zotepine following a switch to perospirone.
Topics: Antipsychotic Agents; Dibenzothiepins; Electrocardiography; Female; Haloperidol; Heart Rate; Humans; | 2012 |
Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Death, Sudden, Cardiac; Female; Haloperidol; Hosp | 2012 |
A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Death, Sudden, Cardiac; Electrocardiography; Female; Hal | 2012 |
Drug-drug interactions contributing to QT prolongation in cardiac intensive care units.
Topics: Amiodarone; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Anti-Infective Agents; Antipsychotic Agents | 2013 |
Dual rate-dependent cardiac electrophysiologic effects of haloperidol: slowing of intraventricular conduction and lengthening of repolarization.
Topics: Action Potentials; Animals; Antipsychotic Agents; Bundle of His; Delayed Rectifier Potassium Channel | 2003 |
Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient.
Topics: Administration, Oral; Adult; Critical Illness; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Excellent review of psychotropic drug-induced torsade de pointes.
Topics: Chronobiology Disorders; Haloperidol; Humans; Long QT Syndrome; Schizophrenia; Torsades de Pointes | 2005 |
A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Arrhythmias, Cardiac; Dementia; Electrocardiography; | 2005 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
QT PRODACT: usability of miniature pigs in safety pharmacology studies: assessment for drug-induced QT interval prolongation.
Topics: Animals; Blood Pressure; Databases, Factual; Electrocardiography; Haloperidol; Heart Rate; Long QT S | 2005 |
Drug-induced Brugada syndrome with ST-T wave alternans and long QT.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Arrhythmias, Cardiac; | 2007 |
Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Europe; Haloperidol; Humans; | 2007 |
Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature.
Topics: Aged, 80 and over; Antipsychotic Agents; Combined Modality Therapy; Dementia, Multi-Infarct; Electro | 2007 |
Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 Enzyme System; Drug Therapy, Combination | 2008 |
Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill.
Topics: Adult; Alcoholism; Cardiomyopathy, Dilated; Delirium; Dose-Response Relationship, Drug; Electrocardi | 1993 |
Cardiac effects of haloperidol and carbamazepine treatment.
Topics: Carbamazepine; Electrocardiography; Haloperidol; Humans; Long QT Syndrome; Prevalence; Retrospective | 1996 |
Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Drug Therapy, Combination; Electr | 1996 |
The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes.
Topics: Animals; Antipsychotic Agents; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Chann | 1997 |
Haloperidol-induced torsade de pointes.
Topics: Adult; Antipsychotic Agents; Electrocardiography; Female; Haloperidol; Humans; Long QT Syndrome; Tor | 1999 |
[Treatment of alcohol delirium can cause sudden cardiac death].
Topics: Adult; Alcohol Withdrawal Delirium; Antipsychotic Agents; Death, Sudden, Cardiac; Haloperidol; Human | 1997 |
Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dogs; Dopamine Antagonists; Haloperidol; Long QT | 2000 |
The association between intravenous haloperidol and prolonged QT interval.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Cohort Studies; Confidence Intervals; Cross-Sectio | 2001 |
Prolongation of QTc interval and antipsychotics.
Topics: Antipsychotic Agents; Death, Sudden, Cardiac; Haloperidol; Humans; Long QT Syndrome; Thioridazine; T | 2002 |
Prolongation of QTc interval and antipsychotics.
Topics: Antipsychotic Agents; Death, Sudden, Cardiac; Drug Administration Schedule; Drug Labeling; Drug Moni | 2002 |
Prolonged Q-T interval and hypokalemia caused by haloperidol.
Topics: Arrhythmias, Cardiac; Electrocardiography; Female; Haloperidol; Humans; Hypokalemia; Long QT Syndrom | 1989 |